 About the cover Jul. 2015; Volume 34 Issue 7 |
In July 2000, the US FDA approved tamoxifen to reduce the risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation. Tamoxifen is the first medication to be approved for DCIS, which accounts for nearly 20 percent of all newly diagnosed breast cancer cases. From The Coming Cancer Breakthroughs. |
Perspective
Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance
Xiao Xu
[ Abstract 1796] [ PDF Full-text 2451] [ HTML Full-text 1242] Epub: 2015-7-8 doi: 10.1186/s40880-015-0029-3
Original Article
Insight into early-phase trials for lung cancer in the United States
Jin-Ji Yang and Yi-Long Wu
[ Abstract 1314] [ PDF Full-text 1921] [ HTML Full-text 1384] Epub: 2015-7-11 doi: 10.1186/s40880-015-0027-5
Review
Predictive biomarkers in precision medicine and drug development against lung cancer
Bingliang Fang, Reza J Mehran, John V Heymach and Stephen G Swisher
[ Abstract 1330] [ PDF Full-text 1747] [ HTML Full-text 1250] Epub: 2015-7-3 doi: 10.1186/s40880-015-0028-4
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough
Fei Zhou and Cai-Cun Zhou
[ Abstract 1255] [ PDF Full-text 1438] [ HTML Full-text 1231] Epub: 2015-7-18 doi: 10.1186/s40880-015-0036-4
Global efforts in conquering lung cancer in China
Li Yan and Li Xu
[ Abstract 1281] [ PDF Full-text 1322] [ HTML Full-text 1146] Epub: 2015-7-28 doi: 10.1186/s40880-015-0034-6
Letter to the Editor
Early-Phase Oncology Research Training (EFFORT) program: a Hengrui-USCACA joint scholarship
Li Yan and Li Xu
[ Abstract 1748] [ PDF Full-text 1865] [ HTML Full-text 1353] Epub: 2015-7-8 doi: 10.1186/s40880-015-0035-5
